Furthermore, we evaluated CD34, a marker of angiogenesis in cervical cancer, in HT-29, YUMC-C1, and YUMC-C2 cell xenograft tumors; the results demonstrated that angiogenesis activity was significantly induced in the drug-resistant and metastatic colon cancer tumor tissue treated with oxaliplatin and lenvatinib (Figure 6A,B). This evidence concerns the gene CD34 and cervical carcinoma.